HCV. In the event GCOR must obtain a license from [...***...] (or its successor in interest) to Patent Rights in order to commercialize an HCV Licensed Product, EPMN's minimum royalty as result of royalty credits under this Section 3.2 will be reduced to [...***...] of Net Sales of such HCV Licensed Product.
Appears in 2 contracts
Sources: License Agreement (Epimmune Inc), License Agreement (Genencor International Inc)